Protocol Biopsies in Delayed Graft Function Kidney Transplants From Brain‐Dead Donors

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Amanda Ahlmark, Ville Sallinen, Anne Räisänen‐Sokolowski, Kaisa Ahopelto, Marko Lempinen, Jouni Lauronen, Ilkka Helanterä
Natura: Artículo Open Access
Pubblicazione: Wiley 2025
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867019390793285632
author Amanda Ahlmark
Ville Sallinen
Anne Räisänen‐Sokolowski
Kaisa Ahopelto
Marko Lempinen
Jouni Lauronen
Ilkka Helanterä
author_facet Amanda Ahlmark
Ville Sallinen
Anne Räisänen‐Sokolowski
Kaisa Ahopelto
Marko Lempinen
Jouni Lauronen
Ilkka Helanterä
Amanda Ahlmark
Ville Sallinen
Anne Räisänen‐Sokolowski
Kaisa Ahopelto
Marko Lempinen
Jouni Lauronen
Ilkka Helanterä
collection Wiley Open Access
contents Protocol Biopsies in Delayed Graft Function Kidney Transplants From Brain‐Dead Donors Amanda Ahlmark Ville Sallinen Anne Räisänen‐Sokolowski Kaisa Ahopelto Marko Lempinen Jouni Lauronen Ilkka Helanterä Clinical Transplantation ABSTRACTBackgroundDelayed graft function (DGF) is a significant challenge in deceased donor kidney transplantation, impacting approximately one third of patients and is associated with acute rejection. Post‐transplant acute rejection is monitored in kidneys with DGF through sequential protocol biopsies in 7–10‐day intervals, according to guidelines based on research done before the current era of immunosuppression treatment. As acute rejection rates have decreased, there is a need to reevaluate the rationale of protocol biopsies.MethodsWe studied the histology of all biopsies taken during the first month post‐transplant among recipients of brain‐dead donor kidneys with DGF at our institution during 2006–2023. All recipients received corticosteroids as induction. Anti‐thymocyte globulin was additionally administered to 3% and 18% receive basiliximab.ResultsA total of 1022 biopsies were studied from 678 recipients. Of the 678 recipients, 178 (26%) had rejection. Most acute rejection episodes occurred 7–10 days post‐transplant. In case of no rejection in the first biopsy, rejection was found in 10% of the cases with subsequent biopsies. No risk factors for acute rejection in these later biopsies could be identified in regression analysis. The presence of donor‐specific human leukocyte antibodies was associated with higher rates of antibody‐mediated rejection during the first post‐transplant month (20% vs. 1.3%, p < 0.001).ConclusionsThe first biopsy post‐transplant in DGF kidneys has an important role in identifying early acute rejection. Of the patients with no rejection in the first biopsy, only 10% had a rejection in the second biopsy. Cases with borderline findings progressed to rejection in approximately one third of the cases. These data reflect the rate of early TCMR in deceased donor kidney transplants when 79% of patients did not receive an anti‐T cell induction antibody. 10.1111/ctr.70228 http://creativecommons.org/licenses/by-nc/4.0/
doi_str_mv 10.1111/ctr.70228
format Artículo Open Access
id wiley_oa_10_1111_ctr_70228
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Protocol Biopsies in Delayed Graft Function Kidney Transplants From Brain‐Dead Donors
Amanda Ahlmark
Ville Sallinen
Anne Räisänen‐Sokolowski
Kaisa Ahopelto
Marko Lempinen
Jouni Lauronen
Ilkka Helanterä
Clinical Transplantation
Protocol Biopsies in Delayed Graft Function Kidney Transplants From Brain‐Dead Donors Amanda Ahlmark Ville Sallinen Anne Räisänen‐Sokolowski Kaisa Ahopelto Marko Lempinen Jouni Lauronen Ilkka Helanterä Clinical Transplantation ABSTRACTBackgroundDelayed graft function (DGF) is a significant challenge in deceased donor kidney transplantation, impacting approximately one third of patients and is associated with acute rejection. Post‐transplant acute rejection is monitored in kidneys with DGF through sequential protocol biopsies in 7–10‐day intervals, according to guidelines based on research done before the current era of immunosuppression treatment. As acute rejection rates have decreased, there is a need to reevaluate the rationale of protocol biopsies.MethodsWe studied the histology of all biopsies taken during the first month post‐transplant among recipients of brain‐dead donor kidneys with DGF at our institution during 2006–2023. All recipients received corticosteroids as induction. Anti‐thymocyte globulin was additionally administered to 3% and 18% receive basiliximab.ResultsA total of 1022 biopsies were studied from 678 recipients. Of the 678 recipients, 178 (26%) had rejection. Most acute rejection episodes occurred 7–10 days post‐transplant. In case of no rejection in the first biopsy, rejection was found in 10% of the cases with subsequent biopsies. No risk factors for acute rejection in these later biopsies could be identified in regression analysis. The presence of donor‐specific human leukocyte antibodies was associated with higher rates of antibody‐mediated rejection during the first post‐transplant month (20% vs. 1.3%, p < 0.001).ConclusionsThe first biopsy post‐transplant in DGF kidneys has an important role in identifying early acute rejection. Of the patients with no rejection in the first biopsy, only 10% had a rejection in the second biopsy. Cases with borderline findings progressed to rejection in approximately one third of the cases. These data reflect the rate of early TCMR in deceased donor kidney transplants when 79% of patients did not receive an anti‐T cell induction antibody. 10.1111/ctr.70228 http://creativecommons.org/licenses/by-nc/4.0/
title Protocol Biopsies in Delayed Graft Function Kidney Transplants From Brain‐Dead Donors
topic Clinical Transplantation
url https://onlinelibrary.wiley.com/doi/10.1111/ctr.70228